Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2024
Reporting Period: Specific event date of June 26, 2024.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate action regarding share repurchases.
Material Changes
The Board of Directors authorized a new Stock Buy Back Program on June 26, 2024. Key terms include:
- Authorization Amount: Up to $20,000,000 in maximum value of common stock.
- Execution Methods: Open market transactions, privately negotiated transactions, or other methods compliant with Rule 10b-18.
- Duration: The program expires in 12 months from the authorization date.
- Obligation: The program does not obligate the Company to purchase any specific number of shares.
- Flexibility: The Board may terminate, increase, or decrease the authorization at any time.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of specific risks beyond the standard discretion of the Board to modify the buyback program. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the current share price to assess the potential number of shares purchasable under the $20 million authorization.
- Review the Company's cash balance in the most recent 10-Q or 10-K to determine the immediate capacity to fund the buyback.
- Monitor future 8-K filings for actual execution of share repurchases under this program.
- Confirm the expiration date of the program (June 26, 2025) for timeline planning.